The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma
Open accessAbstract
Focal adhesion kinase (FAK) overexpression is frequently found in ovarian and other cancers and is predictive of poor clinical outcome. In the current study, we characterized the biological and therapeutic effects of a novel FAK inhibitor, TAE226. Taxane-sensitive (SKOV3ip1 and HeyA8) and taxane-resistant (HeyA8-MDR) cell lines were used for in vitro and in vivo therapy experiments using TAE226 alone and in combination with docetaxel. Assessment of cytotoxicity, cell proliferation [proliferating cell nuclear antigen (PCNA)], angiogenesis (CD31), and apoptosis (terminal nucleotidyl transferase–mediated nick end labeling) were done by immunohistochemistry and immunofluorescence. In vitro, TAE226 inhibited the phosphorylation of FAK at both Y397 and Y861 sites, inhibited cell growth in a time- and dose-dependent manner, and enhanced docetaxel-mediated growth inhibition by 10- and 20-fold in the taxane-sensitive and taxane-resistant cell lines, respectively. In vivo, FAK inhibition by TAE226 significantly reduced tumor burden in the HeyA8, SKOV3ip1, and HeyA8-MDR models (46–64%) compared with vehicle-treated controls. However, the greatest efficacy was observed with concomitant administration of TAE226 and docetaxel in all three models (85–97% reduction, all P values <0.01). In addition, TAE226 alone and in combination with chemotherapy significantly prolonged survival in tumor-bearing mice. Even in larger tumors, combination therapy with TAE226 and docetaxel resulted in tumor regression. The therapeutic efficacy was related to reduced pericyte coverage, induction of apoptosis of tumor-associated endothelial cells, and reduced microvessel density and tumor cell proliferation. The novel FAK inhibitor, TAE226, offers an attractive therapeutic approach in ovarian carcinoma. [Cancer Res 2007;67(22):10976–83]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., Jennings, N. B., Armaiz-Pena, G., Bankson, J. A., Ravoori, M., et al. (2006) · Nature Medicine · doi:10.1038/nm1447 · Cited by 1,320
Self-citation
Cited by
FAK in cancer: mechanistic findings and clinical applications
Sulzmaier, F. J., Jean, C., & Schlaepfer, D. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3792 · Cited by 1,381
Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis
Zhao, X., & Guan, J.-L. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.11.001 · Cited by 835
Signal transduction by focal adhesion kinase in cancer
Zhao, J., & Guan, J.-L. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9165-4 · Cited by 604
FAK signaling in human cancer as a target for therapeutics
Lee, B. Y., Timpson, P., Horvath, L. G., & Daly, R. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.10.001 · Cited by 425
The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer
Tiede, S., Meyer-Schaller, N., Kalathur, R. K. R., Ivanek, R., Fagiani, E., Schmassmann, P., Stillhard, P., Häfliger, S., Kraut, N., Schweifer, N., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0083-1 · Cited by 66
Metadata
- Authors
- Halder, J., Lin, Y. G., Merritt, W. M., Spannuth, W. A., Nick, A. M., Honda, T., Kamat, A. A., Han, L. Y., Kim, T. J., Lu, C., Tari, A. M., Bornmann, W., Fernandez, A., Lopez-Berestein, G., & Sood, A. K.
- Venue
- Cancer Research
- Published
- 2007-11-15
- Volume
- 67
- Issue
- 22
- Pages
- 10976-10983
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2165905376
- Cited by
- 205
- References
- 1
- FWCI
- 15.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-2667
- The paper
- Halder, J., Lin, Y. G., Merritt, W. M., Spannuth, W. A., Nick, A. M., Honda, T., Kamat, A. A., Han, L. Y., Kim, T. J., Lu, C., Tari, A. M., Bornmann, W., Fernandez, A., Lopez-Berestein, G., & Sood, A. K. (2007). Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-2667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.